The global atypical hemolytic uremic syndrome (ahus) treatment market is expected to garner a market value of USD 1431 Million in 2023 and is expected to accumulate a market value of USD 2308.84 Million by registering a CAGR of 4.9% in the forecast period 2023 to 2033. Growth of the atypical hemolytic uremic syndrome (ahus) treatment market can be attributed to increase in research and development activities to offer various treatments to treat the ailment.
The market for atypical hemolytic uremic syndrome (ahus) treatment registered a CAGR of 3.4% in the historical period 2018 to 2022.
Atypical Hemolytic Uremic Syndrome (aHUS) is a rare, life-threatening disorder that causes abnormal blood clotting in small blood vessels, leading to damage to vital organs such as the kidneys, brain, and heart. The goal of treatment for aHUS is to control the disease and prevent further damage to organs. Treatment of atypical hemolytic uremic syndrome (ahus) treatment include plasma exchange, plasma infusion, immunotherapy, complement inhibitors and supportive care.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 1431 Million |
| Anticipated Forecast Value (2033) | USD 2308.84 Million |
| Projected Growth Rate (2023 to 2033) | 4.9% CAGR |
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
According to market research and competitive intelligence provider Future Market Insights- the market for Atypical hemolytic uremic syndrome (ahus) treatment reflected a value of 3.4% during the historical period, 2018 to 2022.
Increasing prevalence of aHUS, growing awareness and diagnosis of the disease, and the development of new and effective treatments are creating lucrative opportunities for the growth of the market. In terms of treatment type, complement inhibitors have emerged as a popular treatment option for aHUS. Several drugs, including eculizumab (Soliris), ravulizumab (Ultomiris), and pegcetacoplan (Empaveli) have been approved by regulatory agencies for the treatment of aHUS, and additional drugs are in various stages of development.
Geographically, North America and Europe are the leading regions for aHUS treatment due to the high prevalence of the disease in these regions and the availability of advanced healthcare facilities. However, the Asia Pacific region is expected to grow at a significant pace in the coming years due to increasing awareness and diagnosis of the disease and the development of new treatments.
Thus, the market for Atypical hemolytic uremic syndrome (ahus) treatment is expected to register a CAGR of 4.9% in the forecast period 2023 to 2033.
Presence of diagnostic tests along with innovation of new therapies spurring market growth
Although aHUS is a rare disease, the incidence of the disease is increasing, leading to a higher demand for effective treatments. With the availability of more sensitive diagnostic tests, more cases of aHUS are being identified, leading to a higher demand for treatment.
In recent years, new therapies have been developed that specifically target the underlying mechanisms of aHUS, such as complement dysregulation. These therapies offer new treatment options for patients with aHUS. Governments in many countries are taking steps to promote research into rare diseases, including aHUS. This support is helping to drive the development of new therapies and expand access to existing treatments. As more is understood about aHUS, there is growing awareness of the disease among patients, caregivers, and healthcare professionals. This increased awareness is leading to earlier diagnosis and treatment of aHUS, which is helping to improve patient outcomes.
Availability of treatments driving growth of atypical hemolytic uremic syndrome (ahus) treatment market Top of Form
Plasma exchange: Plasma exchange involves removing the patient's plasma and replacing it with donor plasma. This helps to remove the harmful antibodies that are attacking the patient's blood cells and causing damage.
Plasma infusion: Plasma infusion involves giving the patient extra plasma, which contains the proteins that help control blood clotting. This can help to restore normal clotting and prevent further damage.
Immunotherapy: Immunotherapy involves giving medications that suppress the immune system and prevent it from attacking the patient's own cells. These medications may include steroids, monoclonal antibodies, or other immunosuppressive drugs.
Complement inhibitors: Complement inhibitors are medications that block the activity of the complement system, which is a part of the immune system that can cause damage in aHUS. These medications may include eculizumab, ravulizumab, or other complement inhibitors.
Supportive care: Supportive care may include treatments to manage symptoms and complications of aHUS, such as dialysis for kidney failure, blood transfusions to replace damaged blood cells, and medications to control high blood pressure.
Limited availability of treatments affecting market growth for aHUS
The cost of aHUS treatment can be very high, which can limit access to care for some patients. The high cost is due to the complexity of the disease, the need for specialized treatment, and the relatively low patient population. While there are several treatments available for aHUS, including plasma exchange, immunosuppressive therapy, and complement inhibitors, there are limited options for some patients. This can be due to the limited availability of certain treatments or the lack of response to existing therapies.
A lack of awareness and expertise among healthcare professionals can lead to delayed diagnosis and treatment of aHUS. This can result in poorer outcomes for patients. aHUS is a rare disease, which means that the patient population is relatively small. This can make it difficult to conduct clinical trials and develop new treatments. Like any treatment, aHUS therapies can have adverse effects, and some patients may not tolerate the available treatments. All these factors are hampering the growth of the market.
Development of new therapies leading to market growth in North America
The prevalence of aHUS is relatively high in North America compared to other regions, which increases the demand for aHUS treatment. North America has a strong tradition of innovation and technological advancements in the healthcare sector, which has led to the development of new treatments and therapies for aHUS. In addition, the region has a well-established healthcare industry, with advanced healthcare facilities and highly skilled healthcare professionals, which enhances the quality of aHUS treatment.
Governments in North America are taking steps to promote research into rare diseases, including aHUS, and this support is driving the development of new therapies and improving access to existing treatments. There is growing awareness of aHUS among patients, caregivers, and healthcare professionals in North America, leading to earlier diagnosis and treatment of the disease. Thus, North America is expected to possess 44% market share for atypical hemolytic uremic syndrome (ahus) treatment market in 2023.
Government initiatives along with growing prevalence bolstering market growth in Europe
The Europe Atypical Hemolytic Uremic Syndrome (aHUS) Treatment Market is a significant segment of the global aHUS treatment market, driven by a high prevalence of aHUS, technological advancements, government initiatives and support is propelling the growth of the market.
Moreover, growing awareness of aHUS among patients, caregivers, and healthcare professionals in Europe, leading to earlier diagnosis and treatment of the disease. Furthermore, several collaborations and partnerships among healthcare companies, academic institutions, and research organizations are driving the development of new treatments for aHUS. Thus, Europe is expected to possess 38% market share for atypical hemolytic uremic syndrome (ahus) treatment market in 2023.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
Better patient outcomes and presence of trained pharmacists driving growth of hospital pharmacies
Hospital pharmacies are equipped to store and dispense specialized medications, such as complement inhibitors, which are commonly used to treat aHUS. Moreover, they often work in collaboration with healthcare providers to ensure that patients receive the correct medication and dose. This helps to optimize patient outcomes and reduce the risk of adverse events.
Hospital pharmacists are highly trained and have a deep understanding of the drugs they dispense, including their mechanisms of action, side effects, and drug interactions. This expertise is particularly important for aHUS patients, as the disease requires specialized treatment. In addition to these factors, the growing prevalence of aHUS and the increasing use of complement inhibitors for treatment are also contributing to the growing prominence of hospital pharmacies in aHUS treatment. Thus, hospital pharmacies are expected to possess 45% market share for atypical hemolytic uremic syndrome (ahus) treatment market in 2023.
Key players in the atypical hemolytic uremic syndrome (ahus) treatment market are Alexion Pharmaceuticals, Omeros Corporation, Novartis Pharmaceuticals, Hoffmann-La Roche, Chugai Pharmaceutical, Tasly Biopharmaceuticals, Prestige BioPharma, Abbott Medtronic, Teva Pharmaceuticals Ltd., Zydus Pharmaceuticals, Inc.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 1431 Million |
| Market Value in 2033 | USD 2308.84 Million |
| Growth Rate | CAGR of 4.9% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million and CAGR from 2023-2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered | Product Type, Molecule Type, Polymer, Route of Administration, Region |
| Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; MEA |
| Key Countries Profiled | USA, Canada, Brazil, Mexico, Rest of Latin America, Germany, United Kingdom, France, Spain, Italy, Rest of Europe, India, Malaysia, Singapore, Thailand, Rest of South Asia, China, Japan, South Korea, Austria, New Zealand, GCC countries, South Africa, Israel, Rest of MEA |
| Key Companies Profiled | Alexion Pharmaceuticals; Omeros Corporation; Novartis Pharmaceuticals; Hoffmann-La Roche; Chugai Pharmaceutical; Tasly Biopharmaceuticals; Prestige BioPharma; Abbott Medtronic; Teva Pharmaceuticals Ltd.; Zydus Pharmaceuticals, Inc. |
| Customization | Available Upon Request |
In 2023, North America is anticipated to hold 44% of the market for aHUS treatments.
The Asia Pacific market is anticipated to reach USD 2,308.84 million by 2033.
The aHUS therapy market in China is predicted to increase rapidly.
The rising incidence of the illness, greater public knowledge, and the availability of efficient treatment alternatives.
The accessibility of efficient therapies and the rise in demand for personalized care.
| Market Size, 2023 | USD 5,120 million |
|---|---|
| Market Size, 2033 | USD 9,521 million |
| Value-based CAGR from 2023 to 2033 | 6.4% |
| Estimated Market Share in 2023 | USD 103.7 million |
|---|---|
| Forecasted Market Size by 2033 | USD 129.2 million |
| Projected CAGR (2023 to 2033) | 2.2% |
| Expected Market Value (2023) | USD 147.9 Million |
|---|---|
| Projected Forecast Value (2033) | USD 412.4 Million |
| CAGR (2023 to 2033) | 10.8% |
Explore Therapy Area Insights
View Reports
Atypical Hemolytic Uremic Syndrome (aHUS) Treatment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
